Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | LMNA | P02545 | 6/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1833488 | 0.98 | MAPT (0.70) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1953023 | 0.96 | MAPT (0.67) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1835297 | 0.95 | MAPT (0.63) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1834778 | 0.86 | MAPT (0.55) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1835417 | 0.86 | MAPT (0.65) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1835418 | 0.86 | MAPT (0.65) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1836825 | 0.85 | MAPT (0.63) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1836824 | 0.85 | MAPT (0.63) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1831385 | 0.85 | MAPT (0.63) | MAPTLMNANPSR1KMT2AGAA | |
| SCHEMBL1837962 | 0.84 | MAPT (0.52) | MAPTLMNANPSR1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281435-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-10-24 | — | — | US | disclosed |
| US-20110136788-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2322222-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | Takeda Pharmaceutical Company Limited (JP) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136788-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | GPBAR1, GPR35, GRPR | MAPT 4242/4885LMNA 4624/4885NPSR1 98/4885 |
| US-20130281435-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | GPBAR1, GPR35, GRPR | MAPT 4189/4885LMNA 4646/4885NPSR1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.